Eli Lilly & Co. (LLY) Reports In-Line Q3 EPS; Narrows FY11 EPS Outlook
Tweet
Share
E-mailGet Alerts LLY Hot Sheet
Price: $1,184.63 --0%
Revenue Growth %: +26.6%
Financial Fact:
Cost of sales: 1.4B
Today's EPS Names:
YRD, CAG, CALM, More
Revenue Growth %: +26.6%
Financial Fact:
Cost of sales: 1.4B
Today's EPS Names:
YRD, CAG, CALM, More
Join SI Premium – FREE
Eli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $1.13, in-line with the analyst estimate of $1.13. Revenue for the quarter came in at $0 versus the consensus estimate of $6.06 billion.
Eli Lilly & Co. sees FY2011 EPS of $4.30-$4.35, versus prior guidance of $4.25-$4.35 and the consensus of $4.33.
Eli Lilly & Co. sees FY2011 EPS of $4.30-$4.35, versus prior guidance of $4.25-$4.35 and the consensus of $4.33.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eli Lilly (LLY) PT Raised to $1,500 at JPMorgan as Guidance Raise Expected
- Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
- CMS pumps $51M into rural Texas to fight diabetes and obesity
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
